These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2421208)

  • 21. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
    Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
    Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple phosphorylated variants of the high molecular mass subunit of neurofilaments in axons of retinal cell neurons: characterization and evidence for their differential association with stationary and moving neurofilaments.
    Lewis SE; Nixon RA
    J Cell Biol; 1988 Dec; 107(6 Pt 2):2689-701. PubMed ID: 3144556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of two antigens in parkinsonian Lewy bodies.
    Hirsch E; Ruberg M; Portier MM; Dardenne M; Agid Y
    Brain Res; 1988 Feb; 441(1-2):139-44. PubMed ID: 3359227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
    Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
    J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell death mechanisms in Parkinson's disease.
    Jellinger KA
    J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuronal inclusions of Parkinson's disease.
    Gibb WR; Scott T; Lees AJ
    Mov Disord; 1991; 6(1):2-11. PubMed ID: 1848677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid-Finnish type.
    Wisniewski T; Haltia M; Ghiso J; Frangione B
    Am J Pathol; 1991 May; 138(5):1077-83. PubMed ID: 1850958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles.
    Galloway PG; Grundke-Iqbal I; Iqbal K; Perry G
    J Neuropathol Exp Neurol; 1988 Nov; 47(6):654-63. PubMed ID: 2459316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemical localization of synaptic vesicle-specific protein in Lewy body-containing neurons in Parkinson's disease.
    Wakabayashi K; Takahashi H; Obata K; Ikuta F
    Neurosci Lett; 1992 Apr; 138(2):237-40. PubMed ID: 1608535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lewy-body formation is an aggresome-related process: a hypothesis.
    Olanow CW; Perl DP; DeMartino GN; McNaught KS
    Lancet Neurol; 2004 Aug; 3(8):496-503. PubMed ID: 15261611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pathological study of the association between Lewy body disease and Alzheimer's disease.
    Gibb WR; Mountjoy CQ; Mann DM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):701-8. PubMed ID: 2545826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lewy bodies.
    Forno LS
    N Engl J Med; 1986 Jan; 314(2):122. PubMed ID: 3941689
    [No Abstract]   [Full Text] [Related]  

  • 37. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies.
    Hill WD; Lee VM; Hurtig HI; Murray JM; Trojanowski JQ
    J Comp Neurol; 1991 Jul; 309(1):150-60. PubMed ID: 1716646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain.
    Crowther RA; Daniel SE; Goedert M
    Neurosci Lett; 2000 Oct; 292(2):128-30. PubMed ID: 10998565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
    Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.